Updated July 2026. 2024–2026 pipeline shifts: The HSV therapeutic vaccine field has consolidated around mRNA platforms after a major setback. GSK terminated its GSK3943104A HSV therapeutic vaccine program in September 2024 — the Phase 2 TH HSV REC-003 trial (3,000+ participants) failed its primary efficacy endpoint of preventing symptomatic recurrent HSV-2, despite generating adequate antibody responses. Post-hoc analysis suggested insufficient CD8+ T-cell responses — reinforcing that latent HSV control requires strong cellular immunity, not antibodies alone. No safety concerns were identified. Two mRNA candidates now lead the field: Moderna's mRNA-1608 (encoding HSV-2 antigens including gC2, gD2, gE2 based on the Friedman/Awasthi lab platform) completed a Phase 1/2 randomized, observer-blind dose-ranging trial (NCT06033261) on April 25, 2025 in adults 18–55 with recurrent HSV-2 genital herpes. Interim safety and immunogenicity results have been presented, though Moderna has indicated the HSV program is under strategic review. BioNTech's BNT163 — a trivalent LNP-encapsulated mRNA vaccine encoding HSV-2 glycoproteins gC2, gD2, and gE2 — has completed Phase 1 enrollment; Open Forum Infectious Diseases (January 2026, ISDA abstract P-105) reported BNT163 was well tolerated with acceptable safety and induced binding and neutralizing antibody responses to HSV-2 antigens. Earliest realistic public availability of any HSV vaccine remains late 2027–2028, contingent on Phase 3 success.
Comprehensive tracking of herpes simplex virus (HSV) therapeutic vaccine development targeting established HSV-1 (oral herpes) and HSV-2 (genital herpes) infections. HSV affects 3.7 billion globally (67% HSV-1), 491 million (13%) HSV-2. US: ~50% adults HSV-1, 1 in 6 (48 million) ages 14-49 genital herpes (HSV-2). Lifelong latent infection in sensory ganglia - NO CURE with current antivirals (acyclovir, valacyclovir) only suppressing replication not eliminating virus. Therapeutic vaccines aim to boost T-cell immunity clearing latently infected cells, reduce recurrent outbreaks (4-6/year typical HSV-2), decrease viral shedding/transmission (asymptomatic shedding 15-20% days), potentially achieve functional cure. Leading candidates: HerpV (completed Phase 2), VC-2 nanoparticle vaccine (Phase 1/2), Genocea's GEN-003 (discontinued after Phase 2). Novel approaches: mRNA vaccines, viral vector immunotherapies. Complementary to antiviral medications and outbreak management.
Herpes simplex virus affects majority of global population: 3.7 billion people (67% under 50) infected with HSV-1 (oral herpes - "cold sores," though 50% genital HSV-1 from oral sex), 491 million (13%) HSV-2 (genital herpes). US prevalence: ~48 million ages 14-49 genital herpes (1 in 6), higher in women (1 in 5) vs. men (1 in 9), disproportionate in Black/African American populations (38% vs. 12% white). Lifelong infection - virus establishes latency in dorsal root ganglia (sacral S2-S5 for genital, trigeminal for oral), persists indefinitely despite immune response. Recurrent outbreaks: 4-6 episodes/year average HSV-2 (painful genital ulcers lasting 7-10 days), psychological burden profound (depression, anxiety, sexual dysfunction, stigma). Asymptomatic viral shedding 15-20% of days (even without symptoms) → transmission to partners. Neonatal herpes: 1,500 US cases/year from maternal transmission during delivery, 60% mortality untreated, neurological damage survivors. HIV risk: Genital herpes increases HIV acquisition 2-3 fold (ulcers provide entry, HSV activates immune cells HIV targets). Current treatment inadequate: Antivirals (acyclovir, valacyclovir, famciclovir) suppress viral replication but don't eliminate latent virus, require daily dosing (suppressive therapy), expensive ($200-500/month without insurance), reduce outbreaks 70-80% and shedding 50% but don't cure. Therapeutic vaccines offer hope: Boosting cellular immunity to clear latently infected neurons, reducing outbreak frequency >80%, decreasing shedding/transmission, potentially functional cure (virus remains but immune control prevents reactivation).
📊 View all HSV therapeutic vaccine trials on ClinicalTrials.gov →
🌍 CDC Genital Herpes Information →
🌍 WHO Herpes Fact Sheet →
🌍 NIAID Genital Herpes →
📰 Latest Herpes Vaccine News (Google) →